## Nikita V Lomakin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9614181/publications.pdf

Version: 2024-02-01

1937457 1588896 9 261 4 8 citations h-index g-index papers 10 10 10 604 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clinical Infectious Diseases, 2021, 73, 531-534.	2.9	202
2	The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research, 2021, 70, 1233-1246.	1.6	35
3	Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 210-215.	1.4	7
4	Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor. European Cardiology Review, 2019, 14, 175-178.	0.7	6
5	Impact of CYP2C19 Polymorphism on Antiplatelet Potency of Prasugrel 5 and 10 mg Daily Maintenance. Cardiology, 2018, 140, 155-162.	0.6	3
6	Historical overview of studies on inflammation in Russia. Inflammation Research, 2013, 62, 441-450.	1.6	2
7	Potential benefits of prasugrel and ticagrelor is diabetics are not substantiated by the Food and Drug Administration adverse event repository. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 142-143.	1.4	1
8	Meta-analyses of incomplete trial datasets: unreliable and potentially misleading. Heart, 2018, 104, 630-631.	1.2	1
9	Evgeny Chazov: first thrombolysis for ischaemic stroke. European Heart Journal, 2019, 40, 2281-2283.	1.0	0